Vivesto's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 18.2% per year.
Key information
-8.5%
Earnings growth rate
10.6%
EPS growth rate
Biotechs Industry Growth
11.5%
Revenue growth rate
-18.2%
Return on equity
-61.7%
Net Margin
-1,766.0%
Next Earnings Update
22 Aug 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vivesto makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
LSE:0N4A Revenue, expenses and earnings (SEK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 24
7
-117
73
0
31 Dec 23
7
-129
84
0
30 Sep 23
2
-284
86
0
30 Jun 23
3
-340
92
0
31 Mar 23
3
-351
95
0
31 Dec 22
3
-357
96
0
30 Sep 22
13
-140
101
0
30 Jun 22
24
-99
107
0
31 Mar 22
29
-118
111
0
31 Dec 21
29
-133
124
0
30 Sep 21
-184
-348
88
0
30 Jun 21
-195
-354
108
0
31 Mar 21
-199
-376
146
0
31 Dec 20
4
-210
185
0
31 Oct 20
205
-59
83
0
31 Jul 20
205
-24
73
0
30 Apr 20
206
-11
226
0
31 Jan 20
4
-196
113
0
31 Oct 19
6
-167
85
0
31 Jul 19
9
-210
60
0
30 Apr 19
10
-201
52
0
31 Jan 19
14
-154
107
0
31 Oct 18
13
-153
106
0
31 Jul 18
13
-117
106
0
30 Apr 18
12
-118
109
0
31 Jan 18
10
-128
115
0
31 Oct 17
10
-139
126
0
31 Jul 17
8
-155
135
0
30 Apr 17
7
-160
139
0
31 Jan 17
7
-151
139
0
31 Oct 16
16
-137
141
0
31 Jul 16
19
-139
148
0
30 Apr 16
23
-142
156
0
31 Jan 16
26
-139
150
0
31 Oct 15
18
-141
136
0
31 Jul 15
19
-124
122
0
30 Apr 15
19
-117
111
0
31 Jan 15
23
-125
123
0
31 Oct 14
26
-128
129
0
31 Jul 14
28
-120
124
0
30 Apr 14
30
-105
120
0
31 Jan 14
30
-90
109
0
31 Oct 13
35
-75
102
0
31 Jul 13
44
-71
106
0
Quality Earnings: 0N4A is currently unprofitable.
Growing Profit Margin: 0N4A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0N4A is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare 0N4A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0N4A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 0N4A has a negative Return on Equity (-61.66%), as it is currently unprofitable.